Business
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Cellectricon, a collaborative services provider dedicated to advancing drug discovery and research in the areas of chronic pain and neurodegenerative diseases announces a collaboration with StressMarq Biosciences.
3DR Labs will employ Resonance Health’s FerriSmart® software to analyze liver iron concentrations from MRIs and provide summary reports
BryoLogyx Inc., announced that David Crockford has joined the Company as vice president of clinical development and logistics, a new position.
“Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement,” said Satish Jindal, BioMotiv’s chief executive officer.
Pappas Capital, a leading investor in early-stage life sciences companies, has appointed Karen LeVert as Venture Partner to help lead the expansion of the firm’s Specialized Fund Management business, with a focus on identifying attractive investment opportunities in agricultural and other related technologies.
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.
Hypha Discovery Limited, the leading specialist CRO for drug metabolite provision, and Cypex Limited, experts in the provision of recombinant xenobiotic metabolising enzymes, have formed a partnership wherein Hypha can scale-up and purify metabolites made by Cypex enzymes.
Polarean Imaging plc announces that Jonathan Allis, Non-Executive Director, has assumed the role of Chairman with immediate effect.
Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units at a price of $0.20 per Unit.
Corteva, Inc. reported financial results for the quarter ended December 31, 2019 and the full year 2019.